Showing results (231-240 of 253) with videos related to

Sort By:
Pageof 26
Malaria Journal|April 5, 2018
Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017Elizabeth Davlantes, Pedro Rafael Dimbu, Carolina Miguel Ferreira, et al.
Journal of Medicinal Chemistry|February 27, 2014
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1Claire Le Manach, Diego Gonzàlez Cabrera, Frederic Douelle, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2021
Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled TrialSean Wasserman, Angharad Davis, Cari Stek, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 29, 2021
Human Immunodeficiency Virus Infection in Adolescents and Mode of Transmission in Southern Africa: A Multinational Analysis of Population-Based Survey DataAndrea Low, Chloe Teasdale, Kristin Brown, et al.
American Journal of Respiratory and Critical Care Medicine|April 2, 2024
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, et al.
Clinical Pharmacokinetics|March 29, 2025
Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026sJennifer A Hughes, Mauricio Pinilla, Kristina M Brooks, et al.
British Journal of Clinical Pharmacology|May 29, 2025
Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistant tuberculosisMegan Palmer, Yuanxi Zou, Anneke C Hesseling, et al.
British Journal of Clinical Pharmacology|February 17, 2025
Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistant tuberculosisMegan Palmer, Yuanxi Zou, Anneke C Hesseling, et al.
Antimicrobial Agents and Chemotherapy|October 26, 2023
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026sMarije Van Schalkwyk, Adrie Bekker, Eric Decloedt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2023
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 TrialHylke Waalewijn, Alexander J Szubert, Roeland E Wasmann, et al.
Pageof 26